Eli Lilly
Trade Eli Lilly 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About LLY
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies.
LLY Key Statistics
Stock Snapshot
The current Eli Lilly(LLY) stock price is $917.47, with a market capitalization of 867.12B. The stock trades at a price-to-earnings (P/E) ratio of 40.00 and offers a dividend yield of 67.9%.
As of 2026-03-20, Eli Lilly(LLY) stock has fluctuated between $908.53 and $924.53. The current price stands at $917.47, placing the stock +1.0% above today's low and -0.8% off the high.
Eli Lilly(LLY) shares are trading with a volume of 2.38M, against a daily average of 2.66M.
During the past year, Eli Lilly(LLY) stock moved between $623.78 at its lowest and $1,133.95 at its peak.
During the past year, Eli Lilly(LLY) stock moved between $623.78 at its lowest and $1,133.95 at its peak.
LLY News
Key Points Eli Lilly has strong momentum thanks to its leadership in the weight loss market. Vertex Pharmaceuticals' core franchise and newer approvals could...
Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Eli Lilly and Co. (LLY) is preparing a new Phase 2 trial called EMERALD-3 for...
Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. The study, titled “An Adaptive Two-Stage Bioequivalence Study of Subcutaneous...
Analyst ratings
80%
of 35 ratingsMore LLY News
Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Eli Lilly and Company (LLY) is launching a Phase 2 trial titled “A Phase 2, Mu...
RBC Capital says that while the overall tolerability and A1C reductions for Eli Lilly’s (LLY) retatrutide in the TRANSCEND-T2D-1 study were worse compared to Mo...
Deutsche Bank says Eli Lilly’s (LLY) retatrutide showed absolute estimated weight loss of 15% or 13% placebo-adjusted, which compares favorably to Mounjaro’s SU...
Retatrutide’s first Phase III Type 2 Diabetes readout met efficacy expectations and eased tolerability concerns, with 1.9% HbA1c reduction and 15.3% weight loss...
Eli Lilly Retatrutide Shows Strong A1C Reduction And Weight Loss Retatrutide is an investigational once-weekly triple hormone receptor agonist that activates t...
Key Points Eli Lilly's Mounjaro and Zepbound are the leading drugs in the GLP-1 space. The company's GLP-1 success has resulted in a lofty valuation for the s...
Eli Lilly’s (LLY) stock is ticking higher after the pharmaceutical giant reported that its next-generation obesity drug called Retatrutide cleared its first lat...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.